A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

Completed · Phase 2 · Has a placebo group

Conditions studied: Acromegaly

In brief

A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.

Key facts

Study ID

NCT03792555

Run by

Crinetics Pharmaceuticals Inc.

People needed

13

Starts

2019-03-11

Expected to finish

2020-08-12

Last updated by the study team

2025-03-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects 18 to 75 years of age
• Confirmed diagnosis of acromegaly that is controlled on stable doses of octreotide LAR or lanreotide depot
• Females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, or using effective method(s) of birth control
• Willing to provide signed informed consent

You may not qualify if…

• Treatment naïve acromegaly subjects
• Prior treatment with paltusotine
• Pituitary surgery within 6 months prior to Screening or radiation therapy at any time prior to the study entry. Pituitary radiation therapy (within 3 to 4 years or more than 4 years prior to study entry) with recently documented elevated IGF-1 may be eligible.
• History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years.
• Use of any investigational drug within the past 30 days or 5 half-lives, whichever is longer
• Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab) or has a history of a positive result
• History of alcohol or substance abuse in the past 12 months
• Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study
• Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities.
• Subjects with symptomatic cholelithiasis
• Subjects with clinically significant abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study
• Subjects who have been taking the following prior medications: pegvisomant (within the last 3 months), dopamine agonists (within the last 3 months) and pasireotide LAR (within the last 6 months)
• Subjects taking octreotide LAR at a dose higher than 40 mg or lanreotide depot at a dose higher than 120 mg
• Subjects who usually take octreotide LAR or lanreotide depot less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)

Where it is running

• Ohio State University — Columbus, Ohio, United States
• The Research Institute of Dallas — Dallas, Texas, United States
• CETI - Centro de Estudos em Terapias Inovadoras — Curitiba, Brazil
• CPQuali Pesquisa Clinica — São Paulo, Brazil
• General Hospital of Athens "Gennimatas" — Athens, Greece
• Semmelweis University Faculty of Medicine — Budapest, Hungary
• University of Pécs Medical School — Pécs, Hungary
• Endocrine, Diabetes and Research Centre, Wellington Hospital — Wellington, New Zealand
• The Centre of Postgraduate Medical Education — Warsaw, Poland
• Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases — Belgrade, Serbia
• National Institute of Endocrinology and Diabetology — Ľubochňa, Slovakia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.